April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review highlights the potential of nanocarriers, like liposomes and solid lipid nanoparticles, in improving targeted drug delivery and effectiveness for androgenetic alopecia treatment, while noting the hurdles of clinical trials and regulatory approval for these advanced methods.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review discusses the potential of nanocarriers like liposomes and nanoparticles to enhance the delivery and efficacy of treatments for androgenetic alopecia, while noting the challenges of clinical translation, such as securing reliable trials and regulatory approval.
May 2025 in “International Journal of Applied Pharmaceutics” This review highlights the potential of nanotechnology in enhancing the treatment of androgenetic alopecia by facilitating targeted drug delivery, improving drug stability, and increasing concentration at target sites, although clinical validation and scalable manufacturing are needed for practical implementation.
June 2025 in “Nanomedicine” This abstract introduces androgenic alopecia as the most common form of non-cicatricial alopecia, which predominantly affects men but also has a significant occurrence in women; however, specific research results or conclusions about treatments or mechanisms are not reported in the summary.
June 2026 in “International Journal of Drug Delivery Technology” This study highlights the potential of polymeric micelles in enhancing the targeted delivery and efficacy of treatments for androgenetic alopecia, by offering improved retention on the scalp, extended release, and reduced systemic side effects compared to conventional therapies like minoxidil and finasteride.